#Paragon trial nejm skin#
“Our technology transforms ordinary skin cells into specialized retinal cells using a cocktail of small molecules,” said Sai Chavala, M.D., co-founder and chief scientific officer of CiRC Biosciences. CiRC Biosciences has provisional patent applications to protect its platform. Pre-clinical studies have shown efficacy in blind mice that demonstrated vision restoration. The company’s novel mechanism of action is designed for direct chemical conversion of fibroblasts into other cell types using a cocktail of small molecules in an 11-day chemical conversion process. Food & Drug Administration (FDA) approved treatments to restore vision loss in Dry AMD or RP. “CiRC Biosciences gives us the science to target retinal diseases that could lead to vision restoration with numerous other applications in the years ahead.”ĬiRC Biosciences is currently advancing pre-clinical development of chemically induced retinal cells for vision restoration in Geographic Atrophy Age-Related Macular Degeneration (Dry AMD), which is the most common cause of irreversible vision loss over the age of 65, and advanced Retinitis Pigmentosa (RP), a genetic disorder that causes tunnel vision and eventual blindness.
“The addition of CiRC Biosciences to our portfolio builds upon our cell and gene therapy platform, an area that has tremendous potential to address serious genetic diseases,” said Jeff Aronin, founder, chairman and chief executive officer of Paragon Biosciences. Chicago, February 2, 2021 – Paragon Biosciences, a life science innovator that creates, invests in and builds life science companies in biopharmaceuticals, cell and gene therapy and synthetic biology utilizing artificial intelligence, today announced the launch of CiRC Biosciences, a cell therapy company developing treatments for serious diseases with high, unmet needs with an initial focus on the eye.
0 kommentar(er)
